Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones.

Histopathology - 1 Jul 2006

Loughrey M B, Beshay V, Dobrovic A, Zalcberg J, Waring P M

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Benzamides
Share to DNA, Neoplasm
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Source

Identifiers

PMID: 16842259
DOI: 10.1111/j.1365-2559.2006.02336.x

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones.PMID 16842259Read ↗

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.Semantic proximity Read ↗

Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.Semantic proximity Read ↗

Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.Semantic proximity Read ↗

Gastrointestinal stromal tumors: who should get imatinib and for how long?Semantic proximity Read ↗

An update on molecular genetics of gastrointestinal stromal tumours.Semantic proximity Read ↗

Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.Semantic proximity Read ↗

[KIT mutation analysis in pathological diagnosis and target-therapy of gastrointestinal stromal tumors: an update].Semantic proximity Read ↗

KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.Semantic proximity Read ↗

Imatinib mesilate for the treatment of gastrointestinal stromal tumour.Semantic proximity Read ↗

Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumorSemantic proximity Read ↗

Molecular subtypes of gastrointestinal stromal tumor requiring specific treatments.Semantic proximity Read ↗

Molecular pathology of c-kit proto-oncogene and development of gastrointestinal stromal tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.